Melanotan I vs Palmitoyl Tetrapeptide-7
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 500 mcg–2 mg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 1–4 weeks | 4–12 weeks |
| Route | subcutaneous | topical |
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. |
| Best For |
What They Have in Common
Melanotan I, Palmitoyl Tetrapeptide-7 are both commonly used for:
Which Has Stronger Evidence?
| Goal | Melanotan I | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Skin Health & Aesthetics | high | high |
Key Studies
Melanotan I
- Use of melanotan I and II in the general population.
BMJ (Clinical research ed.), 2009
- Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Pharmaceutical research, 2000
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Pharmaceutical biotechnology, 1998
Ready to Learn More?
Looking for trusted sources?